NCT06549400Enrolling By Invitation3 期
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- Enrolling By Invitation
- 发起方
- Lupin Ltd.
- 入组人数
- 176
- 试验地点
- 6
- 主要终点
- To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.
研究概览
简要总结
This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.
详细描述
At the completion of the final visit in Study MEX-DM-302 patients who continued to meet the eligibility criteria will be invited to rollover into this open-label study for an additional 18 months. All patients who elect to continue into this open-label study will receive active mexiletine (no placebo).
Mexiletine PR will be started as 167 mg once a day (QD) treatment regimen. The dose will be titrated up at Week 1 to 333 mg and at Week 2 to a maximum dose of 500 mg QD depending on tolerability. If unable to tolerate the escalated dose, the dose will be reduced by one dose step during the titration period of the study to a maximum tolerated dose. Study drug should be taken with food at approximately the same time of the day every day, preferably in the morning (See Section 7 for further details on reconstitution and dosing titration).
Safety assessments include patient- and physician-reported adverse events, standard clinical laboratory evaluations, physical examinations, and vital signs. In addition, ECG, Holter monitors, and echocardiogram assessments will be collected to assess cardiac safety during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DM1 or DM2 diagnosis confirmed genetically;
- •Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age);
- •Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment;
- •Male or non-pregnant female ≥16 years of age;
- •Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg;
- •Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug;
- •No significant cardiac abnormalities as determined by a cardiologist's assessment;
- •Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia;
- •DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4.
排除标准
- •Are pregnant or lactating;
- •Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness;
- •Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min);
- •Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery;
- •Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc.;
- •Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation;
- •High incidence of falls or fall-associated fractures (>5 falls during the past 12 months);
- •Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) on Day 1 (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator;
- •Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment.
- •Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs;
- •Use of any concomitant medications that could increase the cardiac risk;
- •Known allergy to mexiletine or any local anesthetics;
- •Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer (with the exception of participation in the previous MEX-DM-302 study);
- •Wheelchair-bound or bed-ridden;
- •Any cardiac safety associated condition including any of the following criteria detected by cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:
- •PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG
- •Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block
- •Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds)
- •Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia
- •Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves
- •New York Heart Association (NYHA) Class II to IV heart failure
- •Left ventricular systolic dysfunction with ejection fraction <50%
- •Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM))
- •Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant)
- •Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem)
- •Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded
- •Presence of symptomatic coronary artery disease
研究组 & 干预措施
Mexiletine prolonged-release (PR)
Other
Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
干预措施: Mexiletine granules for prolonged-release oral suspension (Drug)
结局指标
主要结局
To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.
时间窗: 78 weeks
Handgrip relaxation time in DM1 patients by mean change in baseline of handgrip relaxation time (seconds) after maximal voluntary isometric contraction (MVIC)
次要结局
- Mean change in MBS scores(78 weeks)
- Assess the long-term safety of mexiletine PR by AEs(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of μL [microliters]) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in units of % [percentage]) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (hematology measured in g/dL [units of grams per deciliter]) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by changes in ECG (HR)(78 weeks)
- Assess the long-term safety of mexiletine PR by vital signs (body temperature)(78 weeks)
- Assess the long-term safety of mexiletine PR by vital signs (respiration)(78 weeks)
- Mean change in VAS(78 weeks)
- Mean change in health-related quality of life(78 weeks)
- Mean change in DM1-Activ-c scale (DM1 patients only)(78 weeks)
- Mean change in time to perform the 10-meter Walk Test(78 weeks)
- Mean change in handgrip relaxation time(78 weeks)
- Mean change in time to perform Timed-up and go (TUG) test(78 weeks)
- Mean change in health-related quality of life measured by EQ-5D(78 weeks)
- Mean change in Myotonic Dystrophy Health Index (MDHI) score (DM1 patients)(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of g/dL) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (urinalysis) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of U/L) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by vital signs (blood pressure)(78 weeks)
- Mean change in Myotonic Dystrophy 2 Health Index (MD2HI) score (DM2 patients)(78 weeks)
- Assess the long-term safety of mexiletine PR by changes in ECG(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mmol/L) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by standard clinical laboratory evaluations (chemistry measured in units of mg/dL) from change in baseline(78 weeks)
- Assess the long-term safety of mexiletine PR by vital signs (pulse)(78 weeks)
- Assess the long-term safety of mexiletine PR by physical examinations(78 weeks)
- To assess the long-term safety of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the MEX-DM-302 study(78 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
终止
3 期
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01575769Hoffmann-La Roche41
终止
3 期
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT00248157Novartis Pharmaceuticals105
终止
3 期
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT00248131Novartis Pharmaceuticals260
已完成
3 期
A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With HypertensionHypertensionNCT00457626Novartis Pharmaceuticals66
终止
3 期
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)Primary Immune ThrombocytopeniaNCT04596995UCB Biopharma SRL43